Journal des sciences biomédicales

  • ISSN: 2254-609X
  • Indice h du journal: 15
  • Note de citation du journal: 5.60
  • Facteur d’impact du journal: 4.85
Indexé dans
  • Genamics JournalSeek
  • Infrastructure nationale des connaissances en Chine (CNKI)
  • Répertoire d'indexation des revues de recherche (DRJI)
  • OCLC - WorldCat
  • Google Scholar
  • SHERPA ROMÉO
  • Laboratoires secrets des moteurs de recherche
Partager cette page

Abstrait

A Note on the Diagnosis of Tumor Metastatic Disease

Natasha Nikon

Not only are brain metastases the most common intracranial neoplasm in adults, but they are also very common in lung cancer patients. The presence of prognostic factors like control of the primary tumor, functional performance status, age, and the number of brain metastases have been used to classify patients. Because some of these patients have a good prognosis, they may benefit from receiving more aggressive treatment. We will go over all of the treatment options for treating brain metastases, which are mostly caused by a lung cancer primary, in thisreview. We willspecifically concentrate on the selection of patientsfor combined modality treatment of brain metastases, such as stereotactic radiosurgery (SRS) and whole brain irradiation; utilizing radio sensitizers; and the neurocognitive impairments that resulted from either SRS or whole brain irradiation. Both small cell lung cancer (SCLC) and non-small cell lung cancer (NSCLC) benefit from prophylactic cranial irradiation (PCI) and its potential neurotoxicity are discussed, asisthe combination treatment of intrathoracic primary disease and solitary brain metastasis. WBRT with an integrated boost to the gross brain metastases, SRS to the surgical bed, fractionated stereotactic radiotherapy, and WBRT with epidermal growth factor receptor (EGFR) inhibitors are also investigated.

Keywords

Lung cancer; PCI; Neurotoxicity

Avertissement: Ce résumé a été traduit à l'aide d'outils d'intelligence artificielle et n'a pas encore été examiné ni vérifié